Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 26, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of shareholding changes and does not contain financial performance data.
Material Changes
The filing details a change in the shareholding of the GlaxoSmithKline US Retirement Savings Plan ("the Plan") resulting from a fund movement on July 20, 2006:
- Previous Holdings: 17,377,834 Ordinary Share ADRs
- New Holdings: 17,339,151 Ordinary Share ADRs
- Net Change: Decrease of 38,683 ADRs
- Average Price: $54.07
Two directors, Dr. J P Garnier and Dr. M M Slaoui, are noted as potentially interested in the shares held within this discretionary fund, similar to other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the specific transaction described above in accordance with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the impact of the 38,683 ADR reduction on the total beneficial ownership of the US Retirement Savings Plan.
- Confirm the specific beneficial interest of Directors Dr. J P Garnier and Dr. M M Slaoui relative to the fund's total holdings.
- Note that this filing does not reflect operational or financial performance for the period.